<DOC>
	<DOC>NCT00073112</DOC>
	<brief_summary>The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.</brief_summary>
	<brief_title>A Study of ABT-751 in Patients With Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Inclusion Criteria Renal Cell Carcinoma. Recurrent tumor. At least 6 weeks postnephrectomy. Able to tolerate normal activities of daily living. Adequate bone marrow, kidney, and liver function. Exclusion Criteria Pregnant or breast feeding. Antitumor therapy within 4 weeks of the start of ABT751 administration. CNS metastasis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>